The relation between plasma tissue factor and oxidized LDL levels in acute coronary syndromes

Pathophysiology of Haemostasis and Thrombosis

Volumn 36, Issue 6, 2007, Pages 290-297

  Emekli Alturfan, Ebru ^a   Basar, Isik ^b   Alturfan, A Ata ^c   Ayan, Faruk ^b   Koldas, Lale ^b   Balci, Huriye ^b   Emekli, Nesrin ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c Vocational School Health Services   (Turkey)

Author keywords

Acute coronary syndromes; Oxidized low density lipoprotein; Plasma; Tissue factor

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; THROMBOPLASTIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY HEIGHT; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ANGINA, UNSTABLE; BLOOD COAGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OXIDATIVE STRESS; THROMBOPLASTIN;

EID: 77952357670     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000296279     Document Type: Article

References (47)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-250.
2. Nemerson Y: Tissue factor and hemostasis. Blood 1988;71:1-8.
3. Schecter AD, Giesen PL, Taby O, Rosenfield CL, Rossikhina M, Fyfe BS, Kohtz DS, Fallon JT, Nemerson Y, Taubman MB: Tissue factor expression in human arterial smooth muscle cells: TF is present in three cellular pools after growth factor stimulation. J Clin Invest 1997;100:2276-2285.
4. Philippou H, Adami A, Amersey RA, Stubbs PJ, Lane DA: A novel specific immunoassay for plasma two chain factor VIIa: investigation of FVIIa levels in normal individuals and in patients with acute coronary syndromes. Blood 1997;89:767-775.
5. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernández-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ: Tissue factor modulates thrombogenicity of human atherosclerotic plaques. Circulation 1997;95:594-599.
6. Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM: Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997;349:769-771.
7. Sarma J, Laan CA, Alam S, Jha A, Fox KA, Dransfield I: Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002;105:2166-2171.
8. Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM, Marchese P, Frelinger AL 3rd, Goldberg RJ, Michelson AD: Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001;38:1002-1006.
9. Croft KD, Beilin LJ, Vandongen R, Rouse I, Masarei J: Leukocyte and platelet function and eicosanoid production in subjects with hypercholesterolaemia. Atherosclerosis 1990;83:101-109.
10. Itabe H, Ueda M: Measurement of plasma oxidized low-density lipoprotein and its clinical implications. J Atheroscler Thromb 2007;14:1-11.
11. Kohno H, Sueshige N, Oguri K, Izumidate H, Masunari T, Kawamura M, Itabe H, Takano T, Hasegawa A, Nagai R: Simple and practical sandwich-type enzyme immunoassay for human oxidatively modified low density lipoprotein using antioxidized phosphatidyl-choline monoclonal antibody and anti-human apolipoprotein-B antibody. Clin Biochem 2000;33:243-253.
12. Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J, Lasaffre E, Vanrenterghem Y, Collen D: Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost 1996;76:663-669.
13. Penny WF, Ben-Yehuda O, Kuroe K, Long J, Bond A, Bhargava V, Peterson JF, McDaniel M, Julicano J, Witztum JL, Ross J Jr, Peterson KL: Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein. J Am Coll Cardiol 2001;37:766-774.
14. Hulthe J, Faberberg B: Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines. Arterioscler Thromb Vasc Biol 2002;22:1162-1167.
15. Tremoli E, Camera M, Maderna P, Sironi L, Prati L, Colli S, Piovella F, Bernini F, Corsini A, Mussoni L: Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor-independent phenomenon. Arterioscler Thromb 1993;13:338-346.
16. Kaneko T, Wada H, Wakita Y, Minamikawa K, Nakase T, Mori Y, Deguchi K, Shirakawa S: Enhanced tissue factor activity and plasminogen activator inhibitor-1 antigen in human umbilical vein endothelial cells incubated with lipoproteins. Blood Coagul Fibrinolysis 1994;5:385-392.
17. Nordin Fredrikson G, Hedblad B, Berglund G, Nilsson J: Plasma oxidized LDL: a predictor for acute myocardial infarction? J Intern Med 2003;253:425-429.
18. Meisinger C, Baumert J, Kusheyinova N, Loewel H, Koenig W: Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 2005;112:651-657.
19. Holvoet P, Kritchevsky SB, Tracy RP, Mertens A, Rubin SM, Butler J, Goodpaster B, Harris TB: The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well functioning elderly people in the health, aging, and body composition cohort. Diabetes 2004;53:1068-1073.
20. Shimada K, Mokuno H, Matsunaga E, Miyazaki T, Sumiyoshi K, Miyauchi K, Daida H: Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis 2004;174:343-347. (Pubitemid 38597092)
21. Johnston N, Jernberg T, Lagerqvist B, Sieg-bahn A, Wallentin L: Oxidized low-density lipoprotein as a predictor of outcome in patients with unstable coronary artery disease. Int J Cardiol 2006;113:167-173.
22. Ndrepepa G, Braun S, von Beckerath N, Mehilli J, Gorchakova O, Vogt W, Schömig A, Kastrati A: Oxidized low density lipoproteins, statin therapy and severity of coronary artery disease. Clin Chim Acta 2005;360:178-186.
23. Casscells W, Naghavi M, Willerson JT: Vulnerable atherosclerotic plaque: a multifocal disease. Circulation 2003;107:2072-2075.
24. Ehara S, Ueda M, Naruko T, Haze K, Matsuo T, Ogami M, Ikura Y, Itabe H, Komatsu R, Yoshiyama M, Takeuchi K, Yoshikawa J: Pathophysiological role of oxidized low-density lipoprotein in plaque instability in coronary artery diseases. J Diabetes Complications 2002;16:60-64.
25. Tedgui A, Mallat Z: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006;86:515-581.
26. Nathan C: Points of control in inflammation. Nature 2002;420:846-852.
27. Drake TA, Hannani K, Fei HH, Lavi S, Berliner JA: Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells. Am J Pathol 1991;138:601-607.
28. Wada H, Kaneko T, Wakita Y, Minamikawa K, Nagaya S, Tamaki S, Deguchi K, Shirakawa S: Effect of lipoproteins on tissue factor activity and PAI-II antigen in human monocytes and macrophages. Int J Cardiol 1994;47:21-25.
29. Witztum JL, Steinberg D: The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc Med 2001;11:93-102.
30. Steinberg D, Witztum JL: Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 2002;105:2107-2111.
31. Landmesser U, Harrison DG: Oxidant stress as a marker for cardiovascular events: Ox marks the spot. Circulation 2001;104:2638-2640.
32. Fong LG, Albert TSE, Hom SE: Inhibition of the macrophage-induced oxidation of low density lipoprotein by interferon-7. J Lipid Res 1994;35:893-904.
33. Zweier JL, Broderick R, Kuppusamy P, Thompson-Gorman S, Lutty GA: Determination of the mechanism of free radical generation in human aortic endothelial cells exposed to anoxia and reoxygenation. J Biol Chem 1994;269:24156-24162.
34. Golino P, Ragni M, Cirillo P, Avvedimento VE, Feliciello A, Esposito N, Scognamiglio A, Trimarco B, Iaccarino G, Condorelli M, Chiariello M, Ambrosio G: Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nat Med 1996;2:35-40.
35. Kuge Y, Kume N, Ishino S, Takai N, Ogawa Y, Mukai T, Minami M, Shiomi M, Saji H: Prominent lectin-like oxidized low density lipoprotein (LDL) receptor-1 (LOX-1) expression in atherosclerotic lesions is associated with tissue factor expression and apoptosis in hypercholesterolemic rabbits. Biol Pharm Bull 2008;31:1475-1482.
36. Moons AHM, Levi M, Peters RJG: Tissue factor and coronary artery disease. Cardiovasc Res 2002;53:313-325.
37. Moreno PR, Bernardi VH, Lopez-Cullear J, Murcia AM, Palacios IF, Gold H, Mehran R, Sharma SK, Nemerson Y, Fuster V, Fallon J T: Macrophages, smooth muscle cells, and tissue factor in unstable angina: implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996;94: 3090-3097.
38. Del Turco S, De Caterina R: Biology and physiopathology of tissue factor and its relevance for ca rdiovascular diseases. Ital Heart J Suppl 2003;4:559-568.
39. Misumi K, Ogawa H, Yasue H, Soejima H, Suefuji H, Nishiyama K, Takazoe K, Kugiyama K, Tsuji I: Comparison of plasma tissue factor levels in unstable and stable angina pectoris. Am J Cardiol 1998;81:22-26.
40. Suefuji H, Ogawa H, Yasue H, Kaikita K, Soejima H, Motoyama T, Mizuno Y, Oshima S, Saito T, Tsuji I, Kumeda K, Kamikubo Y, Nakamura S: Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 1997;134:253-259.
41. Soejima H, Ogawa H, Yasue H, Kaikita K, Nishiyama K, Misumi K, Takazoe K, Miyao Y, Yoshimura M, Kugiyama K, Nakamura S, Tsuji I, Kumeda K: Heigthened tissue factor associated with tissue factor pat hway inhibitor and prognosis in patients with unstable angina. Circulation 1999;99:2908-2913.
42. Freyssinet JM: Cellular microparticles: what are they bad or good for? J Thromb Haemost 2003;1:1655-1662.
43. Hugel B, Martinez MC, Kunzelmann C, Freyssinet JM: Membrane microparticles: two sides of the coin. Physiology (Bethesda) 2005;20:22-27.
44. Panes O, Matus V, Sáez CG, Quiroga T, Pereira J, Mezzano D: Human platelets synthesize and express functional tissue factor. Blood 2007;109:5242-5250.
45. Satta N, Freyssinet JM, Toti F: The significance of human monocyte thrombomodulin during membrane vesiculation and after stimulation by lipopolysaccharide. Br J Haematol 1997;96:534-542.
46. Bilgen D, Sönmez H, Ekmekçi H, Ulutin T, Oztürk Z, Kökoǧlu E, Bayram C, Soner A, Domani̧ N: The relationship of TFPI, Lp(a), and oxidized LDL antibody levels in patients with coronary artery disease. Clin Biochem 2005;38:92-96.
47. Matsumoto N, Nomura S, Kamihata H, Kimura Y, Iwasaka T: Increased level of oxidized LDL-dependent monocyte-derived microparticles in acute coronary syndrome. Thromb Haemost 2004;91:146-154.